Zealand Pharma (ZLDPF) Stock Forecast & Price Target

Compare

188 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZLDPF Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Zealand

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZLDPF Stock 12 Month Forecast

Average Price Target

$134.13

▲(70.74% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Zealand Pharma in the last 3 months. The average price target is $134.13 with a high forecast of $155.66 and a low forecast of $118.30. The average price target represents a 70.74% change from the last price of $78.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","81":"$81","106":"$106","131":"$131","156":"$156"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155.662,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$155.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$134.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118.30312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$118.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,81,106,131,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.88,82.01707692307691,88.15415384615385,94.29123076923076,100.4283076923077,106.56538461538462,112.70246153846153,118.83953846153847,124.97661538461539,131.1136923076923,137.25076923076924,143.38784615384617,149.52492307692307,{"y":155.662,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.88,80.36076923076922,84.84153846153846,89.32230769230769,93.80307692307692,98.28384615384616,102.76461538461538,107.24538461538461,111.72615384615384,116.20692307692308,120.6876923076923,125.16846153846154,129.64923076923077,{"y":134.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.88,79.14331692307692,82.40663384615384,85.66995076923077,88.9332676923077,92.19658461538461,95.45990153846154,98.72321846153847,101.9865353846154,105.24985230769231,108.51316923076924,111.77648615384615,115.03980307692308,{"y":118.30312,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":131.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.51,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$155.66

Average Price Target$134.13

Lowest Price Target$118.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon

J.P. Morgan

$163.45→$155.66

Buy

98.14%

Upside

Reiterated

12/08/25

Zealand Pharma price target lowered to DKK 1,000 from DKK 1,050 at JPMorganZealand Pharma price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan

Kerry Holford

Berenberg Bank

$128.42

Buy

63.47%

Upside

Reiterated

12/04/25

Zealand Pharma (ZLDPF) Gets a Buy from Berenberg Bank

Xian Deng

UBS

$118.3

Buy

50.59%

Upside

Initiated

09/23/25

Zealand Pharma (ZLDPF) Receives a Buy from UBSUBS analyst Xian Deng initiates coverage on Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) with a Buy rating and a price target of DKK760.00.

Cerena Chen

Wells Fargo

$101.18

Buy

28.79%

Upside

Initiated

07/24/25

Zealand Pharma initiated with an Overweight at Wells FargoZealand Pharma initiated with an Overweight at Wells Fargo

Emmanuel Papadakis

Deutsche Bank

$75.5→$62.26

Hold

-20.74%

Downside

Reiterated

07/08/25

Deutsche Bank Remains a Hold on Zealand Pharma (ZLDPF)

Yihan Li

Barclays

$87.17

Buy

10.96%

Upside

Initiated

07/07/25

Zealand Pharma initiated with an Overweight at BarclaysZealand Pharma initiated with an Overweight at Barclays

Kirsty Ross Stewart

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

$140.87

Buy

79.32%

Upside

Initiated

07/01/25

Zealand Pharma initiated with an Outperform at BNP Paribas ExaneZealand Pharma initiated with an Outperform at BNP Paribas Exane

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

05/23/25

European stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10%Elsewhere, Zealand Pharma climbed to the top of the Stoxx 600 with shares up 10%. It came after Cantor Fitzgerald maintained its overweight position on the stock, with analyst Prakhar Agrawal saying in a Friday note to clients that the stock was "trading at a meaningful valuation disconnect relative to the upcoming milestones for petrelintide and the multi-blockbuster opportunity for amylin analogs in obesity."

Laura Hindley

Morgan Stanley

$116.75

Buy

48.61%

Upside

Upgraded

03/21/25

Zealand Pharma upgraded to Overweight from Equal Weight at Morgan StanleyZealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley

Julian Harrison

BTIG

$163.45

Buy

108.05%

Upside

Reiterated

03/17/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (NYSE: RBOT), Alkermes (NASDAQ: ALKS) and Zealand Pharma (Other OTC: ZLDPF)

Martin Parkoi

SEB Enskilda

$124.53→$132.31

Buy

68.42%

Upside

Upgraded

03/12/25

Zealand Pharma upgraded to Buy from Hold at SEB EquitiesZealand Pharma upgraded to Buy from Hold at SEB Equities

Andy Hsieh

William Blair

―

Buy

―

Upgraded

03/07/25

Zealand Pharma upgraded to Outperform from Market Perform at William BlairZealand Pharma upgraded to Outperform from Market Perform at William Blair

Lucy Codrington

Jefferies

$171.23

Buy

117.96%

Upside

Reiterated

12/20/24

Jefferies Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon

J.P. Morgan

$163.45→$155.66

Buy

98.14%

Upside

Reiterated

12/08/25

Zealand Pharma price target lowered to DKK 1,000 from DKK 1,050 at JPMorganZealand Pharma price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan

Kerry Holford

Berenberg Bank

$128.42

Buy

63.47%

Upside

Reiterated

12/04/25

Zealand Pharma (ZLDPF) Gets a Buy from Berenberg Bank

Xian Deng

UBS

$118.3

Buy

50.59%

Upside

Initiated

09/23/25

Zealand Pharma (ZLDPF) Receives a Buy from UBSUBS analyst Xian Deng initiates coverage on Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) with a Buy rating and a price target of DKK760.00.

Cerena Chen

Wells Fargo

$101.18

Buy

28.79%

Upside

Initiated

07/24/25

Zealand Pharma initiated with an Overweight at Wells FargoZealand Pharma initiated with an Overweight at Wells Fargo

Emmanuel Papadakis

Deutsche Bank

$75.5→$62.26

Hold

-20.74%

Downside

Reiterated

07/08/25

Deutsche Bank Remains a Hold on Zealand Pharma (ZLDPF)

Yihan Li

Barclays

$87.17

Buy

10.96%

Upside

Initiated

07/07/25

Zealand Pharma initiated with an Overweight at BarclaysZealand Pharma initiated with an Overweight at Barclays

Kirsty Ross Stewart

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

$140.87

Buy

79.32%

Upside

Initiated

07/01/25

Zealand Pharma initiated with an Outperform at BNP Paribas ExaneZealand Pharma initiated with an Outperform at BNP Paribas Exane

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

05/23/25

Laura Hindley

Morgan Stanley

$116.75

Buy

48.61%

Upside

Upgraded

03/21/25

Zealand Pharma upgraded to Overweight from Equal Weight at Morgan StanleyZealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley

Julian Harrison

BTIG

$163.45

Buy

108.05%

Upside

Reiterated

03/17/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (NYSE: RBOT), Alkermes (NASDAQ: ALKS) and Zealand Pharma (Other OTC: ZLDPF)

Martin Parkoi

SEB Enskilda

$124.53→$132.31

Buy

68.42%

Upside

Upgraded

03/12/25

Zealand Pharma upgraded to Buy from Hold at SEB EquitiesZealand Pharma upgraded to Buy from Hold at SEB Equities

Andy Hsieh

William Blair

―

Buy

―

Upgraded

03/07/25

Zealand Pharma upgraded to Outperform from Market Perform at William BlairZealand Pharma upgraded to Outperform from Market Perform at William Blair

Lucy Codrington

Jefferies

$171.23

Buy

117.96%

Upside

Reiterated

12/20/24

Jefferies Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zealand Pharma

1 Month

xxx

Success Rate

5/8 ratings generated profit

Average Return

+4.96%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +4.96% per trade.

3 Months

xxx

Success Rate

3/8 ratings generated profit

Average Return

+23.85%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of +23.85% per trade.

1 Year

Kerry HolfordBerenberg Bank

Success Rate

2/3 ratings generated profit

Average Return

+9.17%

reiterated a buy rating 7 days ago

Copying Kerry Holford's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +9.17% per trade.

2 Years

xxx

Success Rate

2/8 ratings generated profit

Average Return

-5.53%

reiterated a xxx

rating 12 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -5.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZLDPF Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Sep 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZLDPF has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ZLDPF average Analyst price target in the past 3 months is 134.13.

Each month's total comprises the sum of three months' worth of ratings.

ZLDPF Financial Forecast

ZLDPF Earnings Forecast

Next quarter’s earnings estimate for ZLDPF is -$1.25 with a range of -$1.50 to -$0.90. The previous quarter’s EPS was -$0.90. ZLDPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ZLDPF has Performed in-line its overall industry.

ZLDPF Sales Forecast

Next quarter’s sales forecast for ZLDPF is $25.10M with a range of $1.09M to $70.00M. The previous quarter’s sales results were $7.73M. ZLDPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ZLDPF has Performed in-line its overall industry.

ZLDPF Stock Forecast FAQ

What is ZLDPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Zealand Pharma’s 12-month average price target is 134.13.

What is ZLDPF’s upside potential, based on the analysts’ average price target?

Zealand Pharma has 70.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZLDPF a Buy, Sell or Hold?

Zealand Pharma has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Zealand Pharma’s price target?

The average price target for Zealand Pharma is 134.13. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $155.66 ,the lowest forecast is $118.30. The average price target represents 70.74% Increase from the current price of $78.56.

What do analysts say about Zealand Pharma?

Zealand Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of ZLDPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Zealand Pharma (ZLDPF) Stock Forecast & Price Target

ZLDPF Analyst Ratings

ZLDPF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zealand Pharma

ZLDPF Analyst Recommendation Trends

ZLDPF Financial Forecast

ZLDPF Earnings Forecast

ZLDPF Sales Forecast

ZLDPF Stock Forecast FAQ

Detailed List of Analyst Forecasts